Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis

Table 5 Analysis of factors related to overt bleeding after treatment, n (%)

Characteristics	χ2 test			Binary logistic analysis
	Patients with OBAT (n = 16)	Patients without OBAT (n = 77)	P value	OR (95%CI)	P value
Gender
Male	12 (75.0)	50 (64.9)	0.565
Female	4 (25.0)	27 (35.1)
Age (year)
< 65	7 (43.8)	35 (45.5)	0.901
≥ 65	9 (56.3)	42 (54.5)
Smoking history
No	12 (75.0)	47 (61.0)	0.396
Yes	4 (25.0)	30 (39.0)
Drinking history
No	12 (75.0)	68 (88.3)	0.228	Reference
Yes	4 (25.0)	9 (11.7)		8.512 (1.279-56.655)	0.027
1Chronic disease
No	7 (43.8)	48 (62.3)	0.169	Reference
Yes	9 (56.3)	29 (37.7)		3.929 (0.974-15.855)	0.055
ECOG-PS
0 or 1	14 (87.5)	72 (93.5)	0.346
2	2 (12.5)	5 (6.5)
BMI (kg/m2)
≤ 18.4	2 (12.5)	9 (11.7)	0.668
18.5-23.9	8 (50.0)	47 (61.0)
≥ 24.0	6 (37.5)	21 (27.3)
Weight loss
< 5%	8 (50.0)	31 (40.3)	0.472
≥ 5%	8 (50.0)	46 (59.7)
Primary tumor location
Pylorus	2 (12.5)	23 (29.9)	0.168	Reference
Body	10 (62.5)	28 (36.4)		10.104 (1.287-79.302)	0.028
Cardia	4 (25.0)	26 (33.8)		1.773 (0.209-15.072)	0.600
Cancer stage (AJCC 8th)
Stage III	4 (25.0)	15 (19.5)	0.734
Stage IV	12 (75.0)	62 (80.5)
OBBT status
No	6 (37.5)	55 (71.4)	0.009	Reference
Yes	10 (62.5)	22 (28.6)		7.015 (1.726-28.505)	0.006
Therapeutic regimen
Chemotriplet regimen	5 (31.3)	31 (40.3)	0.761
2Chemodouble- based regimen	11 (68.8)	43 (55.8)
3Monotherapy	0	3 (3.9)
Grade 3/4 TRAEs
No	10 (62.5)	47 (61.0)	0.913
Yes	6 (37.5)	30 (39.0)
Radiographic best response
CR or PR	2 (12.5)	19 (24.7)	0.149	Reference
SD/no CR or no PR	10 (62.5)	52 (67.5)		2.763 (0.462-16.504)	0.265
PD	3 (18.8)	4 (5.2)		14.039 (1.158-170.260)	0.038
NA	1 (6.3)	2 (2.6)		32.043 (1.248-822.685)	0.038

¹Consisting of hypertension, coronary heart disease, cerebral infarction, diabetes, chronic renal failure, and chronic liver disease.

²Regimen included a chemo-doublet regimen, a chemo-doublet plus targeted therapy regimen, and a chemo-doublet plus immune checkpoints inhibitor regimen.

³Fluorouracil monotherapy or immune checkpoints inhibitor monotherapy.

OBAT: Overt bleeding after treatment; OR: Odds ratio; CI: Confidence interval; ECOG-PS: Eastern Corporative Oncology Group Performance Status; BMI: Body mass index; OBBT: Overt bleeding before treatment; TRAEs: Treatment-related adverse events; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NA: Not available.